Month: August 2020

Iconic omnichannel retailer expands next-gen digital customer experiences with eGain

Written by Customer Service on August 20, 2020. Posted in Public Companies.

SUNNYVALE, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading provider of customer engagement solutions, today announced that a leading omnichannel retailer is now offering expanded self-service powered by eGain.The company selected eGain for its deep product capabilities and quick business value. With shoppers going digital in a hurry in the pandemic, the company needed to rapidly expand customer self-service, while controlling operating costs.In a matter of weeks, eGain helped launch virtual assistance and customer messaging to complement existing live chat and knowledge-based customer engagement. Going beyond “meet and greet,” the virtual assistant resolves a broad range of questions on orders, returns, product selection, and store location. Integrated with transactional systems, it now successfully resolves...

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

Written by Customer Service on August 20, 2020. Posted in Public Companies.

First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxisPharmacokinetic and pharmacodynamics data expected in fourth quarter 2020WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the initiation of a Phase 1 Pharmacokinetic (PK) trial for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies. “The initiation of this Phase 1 trial represents...

Conformis Announces Achievement of Second Milestone Under Development and License Agreements

Written by Customer Service on August 20, 2020. Posted in Public Companies.

BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics, under which Conformis is developing patient-specific instrumentation (“PSI”) for use in connection with Stryker’s knee implant offerings. The Company will receive an additional $3.0 million from Stryker for achieving this milestone.“We are pleased to announce the achievement of the second project milestone,” said Mark Augusti, President and Chief Executive Officer. “We believe that this project, as well as the long-term distribution agreement under which Conformis will manufacture and supply PSI to Stryker, will...

Marathon Gold Appoints Lead Consultant for Valentine Feasibility Study

Written by Customer Service on August 20, 2020. Posted in Public Companies.

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to announce the appointment of Ausenco Engineering Canada Inc. (“Ausenco”) as the lead consultant for the Feasibility Study (“FS”) at the Valentine Gold Project in central Newfoundland.As lead consultant for the FS, Ausenco will be responsible for process and facilities design, access and power infrastructure design, capital and operating cost estimation and execution planning. As project manager of the FS, Ausenco will also be coordinating contractor engagement, with a strong focus on local procurement, service providers, and employment. Working in coordination with Ausenco, Marathon has also engaged Moose Mountain Technical Services for open pit mine design, site infrastructure design (waste rock piles and haul...

OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19

Written by Customer Service on August 20, 2020. Posted in Public Companies.

– Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour– 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA – Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagentsGAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Curetis GmbH has obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2,...

Fynske Bank A/S: Delårsrapport 1. halvår 2020

Written by Customer Service on August 20, 2020. Posted in Earnings Releases And Operating Results.

Selskabsmeddelelse nr. 2020/12Flot andet kvartal for Fynske BankFynske Banks regnskab for første halvår af 2020 viser et acceptabelt resultat før skat på 10 mio. kr. efter et solidt andet kvartal. Trods uroen på de finansielle markeder som følge af COVID-19 endte det andet kvartal med et plus på 33 mio. kr.Efter en udfordrende start på 2020 leverede Fynske Bank et flot andet kvartal trods den globale uro på finansmarkederne verdenen over som følge af COVID-19.Det betyder, at bankens halvårsregnskab samlet set ender i et resultat før skat på 10 mio. kr.I samme periode sidste år lød overskuddet før skat på 47,8 mio. kr. Men set i lyset af pandemien betragter banken resultatet som acceptabelt, og direktør Petter Blondeau hæfter sig i særdeleshed ved den positive udvikling fra første kvartal, hvor et underskud før skat på 22,9 mio. kr. er...

Opera Limited announces second quarter 2020 financial results and formation of Nanobank

Written by Customer Service on August 20, 2020. Posted in Earnings Releases And Operating Results.

Opera’s total user base exceeded 360 million monthly active users in the second quarter and grew to a record 379 million users in JulyOpera News reported record monthly active users of 205 million in the second quarter, up 26% year-over-yearPC browser users grew to record 75 million monthly active users, up 15% year over year in the second quarterSecond quarter revenue of $55.4 million; trends improved as the quarter progressed and into the third quarterRecovery well underway with search and advertising revenues improving 32% in July from April and microlending loan disbursements growing 82% from June to JulySecond quarter adjusted EBITDA(1) of $2.9 million, and net income of $17.1 millionAnnouncing the formation of Nanobank – the combination of Opera’s microlending business and Mobimagic to create a category leader in emerging...

Meddelelse nr. 15/2020: Delårsrapport 1. januar – 30. juni 2020

Written by Customer Service on August 20, 2020. Posted in Earnings Releases And Operating Results.

Bestyrelsen for Strategic Investments A/S har på et møde d.d. behandlet selskabets delårsrapport for perioden 1. januar – 30. juni 2020.Resumé:Strategic Investments A/S’s resultat for 2. kvartal 2020 blev på DKK 26,6m før og efter skat svarende til et afkast på 12,0% og en stigning i indre værdi på DKK 0,08 pr. aktie.Resultatet for 1. halvår 2020 blev på DKK -71,4m før og efter skat svarende til et afkast på -22,1% og et fald i indre værdi på DKK 0,21 pr. aktie.Som oprindeligt planlagt afholdtes selskabets ordinære generalforsamling d. 16. april 2020 hvor generalforsamlingen vedtog udbetaling af udbytte på DKK 0,02 pr. aktie svarende til 3% af indre værdi.Selskabets egenkapital var d. 30. juni 2020 DKK 244,9m, svarende til en indre værdi af selskabets aktier på DKK 0,73 pr. aktie.I overensstemmelse med normal praksis offentliggjorde Strategic...

Vitalhub Corp. Announces Acquisition of Intouch With Health Inc.

Written by Customer Service on August 20, 2020. Posted in Mergers And Acquisitions.

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce today that it has acquired all the issued and outstanding shares (the “Acquisition”) of Intouch with Health Inc. (“Intouch”), a UK leader for patient flow management solutions.Through its “Intouch Patient Journey Platform,” Intouch specializes in delivering patient-focused flow management solutions that allow patients to more effectively move throughout a hospital. Intouch has evolved their solutions to support “virtual healthcare” patient interaction placing less reliance on face-to-face interactions. Intouch was founded in 1999 and is headquartered in Cirencester, Gloucestershire, United Kingdom with staff and operations, composed of 38 employees and contractors, located throughout the United Kingdom. Their...

Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases

Written by Customer Service on August 20, 2020. Posted in Public Companies.

BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce it has restarted patient recruitment for its Phase 2a clinical trial in AD which was suspended due to COVID-19 in March 2020, and initiated recruitment for its new Phase 2a clinical trial in AD and PD.The Company’s first Phase 2a trial of its lead compound, ANVS401, is a one-month study in 24 AD patients conducted in collaboration with the Alzheimer Disease Cooperative Study. The study is being conducted in six sites, including the University of California, San Diego, Johns Hopkins, Indiana University, Washington University, Cleveland Clinic, and Columbia University. Prior to suspension...

Month: August 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals